chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pain, Presyncope, Vaccination site pain
Clinical narrative: Headache; Muscle pain in armpits; muscle pain ~4 inches from injection site; Loss of smell for 2 hrs; loss of  taste for 2 hrs; Body aches; Malaise; Approx 30 minutes after vaccine got intense wave ofnausea; Approx 30 minutes after vaccine got intense wave oflightheadedness; Almost passed out; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 17Apr2021 at 14:30 (at the age of 33-year-old), as a single dose for COVID-19 immunisation. Medical history included asthma and COVID-19 and known allergy to penicillin. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included levocetirizine dihydrochloride (XYZAL), bupropion hydrochloride (WELLBUTRIN), montelukast sodium (SINGULAIR), salbutamol (VENTOLIN), fluticasone propionate, salmeterol xinafoate (WIXELA INHUB) and sp (as reported); all for unknown indication from an unknown date and unknown if ongoing. The patient previously received amoxicillin (MANUFACTURER UNKNOWN), levofloxacin (LEVOQUIN), doxycycline (MANUFACTURER UNKNOWN) and paracetamol; oxycodone hydrochloride (PERCOCET); all for unknown indication from an unknown date and experienced drug allergy. On 17Apr2021 at 15:15, the patient experienced headache, muscle pain in armpits, muscle pain approximately 4 inches from injection site (felt like muscle tearing), loss of smell and taste for 2 hours, body aches, malaise. Approximately 30 minutes after vaccine, the patient got intense wave of nausea, light-headedness and almost passed out. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events loss of smell and loss of taste was resolved on 17Apr2021, after the duration of approximately 2 hours. The clinical outcome of the events headache, muscle pain in armpits, muscle pain 4 inches from injection site, body aches, malaise, intense wave of nausea, lightheadedness and almost passed out was resolved on an unspecified date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Immediately had a persistent metallic taste in my mouth; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 11May2021 at 12:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included levothyroxine sodium (LEVOTHYROXIN) from an unknown date, for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received prochlorperazine maleate (COMPAZINE) on an unknown date, for unknown indication and experienced drug allergy. On 11May2021 at 12:00, the patient immediately had a persistent metallic taste in the mouth. The event did not result in a doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event immediately had a persistent metallic taste in mouth was not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test, Rash, Rash papular, Rash pruritic, SARS-CoV-2 test
Clinical narrative: Rash on face specifically cheeks, nose, and between eyes on forehead.; Red, puffy, small bumps, and a little itchy.; Red, puffy, small bumps, and a little itchy; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 21Apr2021 at 14:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to opioid pain killers. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 04May2021 at 15:00, the patient experienced rash on face specifically cheeks, nose and between eyes on forehead and red, puffy, small bumps, and a little itchy. On 30Apr2021, the patient underwent COVID-19 virus test via nasal swab and the result was negative. On an unknown date in May2021, the patient underwent blood test and the result was unknown. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events and included treatment with steroid cream. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events rash on face specifically cheeks, nose and between eyes on forehead and red, puffy, small bumps, and a little itchy was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Hypersensitivity, Rash, Swelling
Clinical narrative: I have a rash all over my body but especially on both legs; the rash and swelling became much more serious; the rash and swelling became much more serious; Had a bad reaction; This is a spontaneous report from a contactable consumer (patient). A 77-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number: EW0172), via an unspecified route of administration, administered in Arm Right on 26Apr2021 (at the age of 77-year-old) as dose 1, single for covid-19 immunisation. Medical history included diabetes mellitus (Verbatim: Diabetes), hypertension (Verbatim: High Blood Pressure), blood cholesterol increased (Verbatim: High cholesterol), asthma (so I am taking some inhalers and I take Levothyroxine), thyroid (Verbatim: Thyroid). Concomitant medication(s) included levothyroxine taken for an unspecified indication, start and stop date were not reported. Caller stated that he had a bad reaction from vaccine. He has a rash all over his body but especially on both legs. He stated he was experiencing some rash in his legs before that (Covid Vaccine), maybe one week before but after that, the rash and swelling became much more serious. As a part of treatment consumer stated he was using over the counter Gold Bond Diabetes Rash Lotion, it is a lotion and he just apply 4 or 5 times a day and cover his entire leg with the lotion. The outcome of events was unknown.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Disorientation, Dizziness, Nausea
Clinical narrative: Nauseous and vomiting; Nauseous and vomiting; Hip pain; Chills; Dizziness; Disorientation; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in left arm on 06May2021 at 12:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included montelukast (MANUFACTURER UNKNOWN), loratadine (MANUFACTURER UNKNOWN) and etynodiol diacetate / ethinylestradiol (KELNOR) for unknown indication from an unknown date and unknown if ongoing. The patient previously received paracetamol (TYLENOL) for unknown indication on an unknown date and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 14:15 (age at vaccination-unknown) as a single dose for COVID-19 immunisation. On 06May2021, at 22:00, the patient experienced nauseous, vomiting, hip pain, chills, dizziness and disorientation. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events of nauseous, vomiting, hip pain, chills, dizziness and disorientation were recovering at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Nauseous and vomiting; Nauseous and vomiting; Hip pain; Chills; Dizziness; Disorientation; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in left arm on 06May2021 at 12:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included montelukast (MANUFACTURER UNKNOWN), loratadine (MANUFACTURER UNKNOWN) and etynodiol diacetate / ethinylestradiol (KELNOR) for unknown indication from an unknown date and unknown if ongoing. The patient previously received paracetamol (TYLENOL) for unknown indication on an unknown date and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 15Apr2021 at 14:15 (age at vaccination-unknown) as a single dose for COVID-19 immunisation. On 06May2021, at 22:00, the patient experienced nauseous, vomiting, hip pain, chills, dizziness and disorientation. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events of nauseous, vomiting, hip pain, chills, dizziness and disorientation were recovering at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash, Vaccination site erythema
Clinical narrative: Huge red mark around where got the shot; Itchiness everywhere beginning 30 minutes after vaccination; Rashes appearing on thighs and stomach within 24 hours and worsening around 30 hours; This is a spontaneous report from a non-contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 07May2021 at 12:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history included allergies to latex and gluten. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive other vaccines within 4 weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 27Apr2021 at 12:30 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. On 07May2021 at 12:30, 30 minutes after vaccination, the patient experienced itchiness everywhere. On 07May2021, within 24 hours, she experienced rashes appearing on thighs and stomach and worsening around 30 hours. On 07May2021 at 13:30, the patient had huge red mark around where she got the shot. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events itchiness everywhere, rashes appearing on thighs and stomach and huge red mark around where she got the shot was not resolved at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Experiencing 3 lymph nodes near left collar bone; This is a spontaneous report from a contactable consumer, the patient. A 28-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 27Apr2021 (at the age of 28-year-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any concomitant medication. On an unknown date in 2021, after taking the vaccine, the patient was experiencing 3 lymph nodes near the left collar bone. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event experiencing 3 lymph nodes near left collar bone was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Rash papular, Vaccination site pain
Clinical narrative: Small rash broke out on back and arms. The rashlooks almost like bumps right before a pimple forms, small and hard, extremely tiny. Not very red. Sporadic around my back only a few down each arm.; At injection site there was a burning sensation a little while after leaving facility; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0175) via an unspecified route of administration in the left arm on 01May2021 at 12:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included seizure and known allergy to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included lamotrigine (LAMICTAL) and topiramate (MANUFACTUER UNKNOWN); all for unknown indications, from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01May2021, the patient experienced at injection site, there was a burning sensation a little while after leaving facility. On 06May2021, 5 days later, the patient had small rash broke out on back and arms and the rash looked almost like bumps right before a pimple forms, small and hard, extremely tiny, not very red. It was sporadic around back and only a few down each arm. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events at injection site there was a burning sensation a little while after leaving facility, small rash which broke out on back and arms and the rash looked almost like bumps right before a pimple forms, small and hard, extremely tiny, not very red, sporadic around back and only a few down each arm was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Gianotti-Crosti syndrome
Clinical narrative: 3 itchy red spots at "my" inguinal region near lymph nodes/ this rash developed further covering full body,centering around inguinal and armpit areas, legs too/ diagnosed as by "my" dermatologist as gianotti-crosti syndrome, caused by vaccine shot.; This is a spontaneous report from a non-contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 16Apr2021 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. The medical history included allergy to dust mites and pollen. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications were not reported. On 19Apr2021, after 3 days of first Pfizer vaccine shot, the patient developed 3 itchy red spots at her inguinal region near lymph nodes. On 24Apr2021, on 8th day, that rash developed further covering full body, centering around inguinal and armpit areas and legs too. On 25Apr2021, on 9th day, the patient went to see urgent care. On 26Apr2021, 10th day, the patient saw her family doctor and confirmed it was caused by COVID-19 vaccine and prescribed medicine and cream. On 27Apr2021, on 11th day,  it was diagnosed as gianotti-crosti syndrome by her dermatologist, caused by vaccine shot. The patient reported that she was recommended to take the second shots by both family doctor and dermatologist, so she went to receive her second shot 3 weeks later, on May7th as planned. The adverse event resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures taken as a result of the reported events included treatment with cetirizine hydrochloride (ZYRTEC), diphenhydramine hydrochloride (BENADRYL), clobetasone cream (MANUFACTURER UNKNOWN) and hydroxyzine (MANUFACTURER UNKNOWN) on unknown dates. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events 3 itchy red spots at inguinal region near lymph nodes, full body rash on inguinal, armpit areas and legs and gianotti-crosti syndrome were resolving at the time of this report. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the left arm on 07May2021 (at the age of 34-years-old) as a single dose for COVID-19 immunisation.   No follow-up attempts are possible. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Nausea, Pain in extremity
Clinical narrative: Chills; Nausea; Soreness in arm; Fatigue; Headache; This is a spontaneous report from a non-contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0182) via an unspecified route of administration in the left arm on 09May2021 at 11:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included naproxen sodium (ALEVE) and ascorbic acid/cyanocobalamin/ergocalciferol/nicotinamide/pyridoxine hydrochloride/retinol/riboflavin/thiamine mononitrate (ONE-A-DAY) gummies; both for unknown indications from unknown date and unknown if on going. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 18Apr2021 at 12:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. On 09May2021 at 21:45, the patient experienced chills, nausea, soreness in arm, fatigue and headache. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, nausea, soreness in arm, fatigue and headache was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain, Paraesthesia, Pyrexia
Clinical narrative: Fever; Body aches; Pins and needles in my hands and feet.; Headache for 4 days; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 22Apr2021 at 18:00 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome and COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. Concomitant medication taken within two weeks of vaccination included amitriptyline (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. The patient previously took metoclopramide (REGLAN) and experienced drug allergy. The patient did not receive any other vaccines within four weeks prior to the vaccination. The most concerning side effect was pins and needles in the patients hands and feet. It started on 22Apr2021 at 20:00, 2 hours after she got her vaccine. It was constant for about 72 hours, and had been off and on daily, since then. Sometimes it would be in other areas, like arms or legs for a few seconds, but mainly it was her hands and feet. The patient also had a headache for 4 days, a fever on 23Apr2021, the day after she got her vaccine, and body aches that lasted about 24 hours. The patient reported she was afraid to get her second dose because she was afraid the pins and needles would get worse. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever and body aches were resolved on 24Apr2021 after the duration of 24 hours and headache was resolved on 26Apr2021 after the duration of 4 days, while that of the event pins and needles in hands and feet was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Memory impairment
Clinical narrative: Brain fog and trouble with short term memory/ It feels like the description of COVID BRAIN FOG but with the vaccine; Trouble with short term memory; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 27Mar2021 at 17:30 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy and cosmetic surgery on 17Mar2021, 10 days before second dose. Prior to the vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included citalopram (MANUFACTURER UNKNOWN), somatropin (HGH), testosterone (MANUFACTURER UNKNOWN), ergocalciferol (VIT D) and multiple (as reported) (MANUFACTURER UNKNOWN); all for unknown indications from unknown dates and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the left arm on 25Feb2021 at 14:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. On 01Apr2021, about a week or so after second dose, the patient had brain fog and trouble with her short-term memory. The patient thought it might be the anaesthesia and pain pills related to cosmetic surgery, but the brain fog had not gone away at almost 6 weeks. It felt like the description of COVID BRAIN FOG but with the vaccine. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events brain fog and trouble with short term memory/ it feels like the description of COVID BRAIN FOG but with the vaccine and trouble with short term memory was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Nausea, Pain, Pyrexia
Clinical narrative: Severe body aches; Chills; Fever; Soreness in injection site; Nausea; Loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 11May2021 at 12:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient did not have relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 20Apr2021 at 10:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. On 11May2021 at 23:00, the patient experienced severe body aches, chills, fever, soreness in injection site, nausea and loss of appetite. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe body aches, chills, fever, soreness in injection site, nausea and loss of appetite was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Severe body aches; Chills; Fever; Soreness in injection site; Nausea; Loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 23-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173) via an unspecified route of administration in the left arm on 11May2021 at 12:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient did not have relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 20Apr2021 at 10:00 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. On 11May2021 at 23:00, the patient experienced severe body aches, chills, fever, soreness in injection site, nausea and loss of appetite. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe body aches, chills, fever, soreness in injection site, nausea and loss of appetite was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Pain in extremity, Paraesthesia
Clinical narrative: Tingling pinky finger in arm of vaccination site; Severe sore arm; Muscle aches; This is a spontaneous report from a contactable consumer. A 38-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 11May2021(at the age of 38-years-old) as a single dose for COVID-19 immunisation. The medical history was not reported. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. It was unknown whether the patient received any other vaccines within four weeks prior to the vaccination. It was unknown whether the patient received any other medications within two weeks of the vaccination. On 12May2021, the patient experienced tingling pinky finger in arm of vaccination site, severe sore arm and muscle aches. The adverse events did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the events tingling pinky finger in arm of vaccination site, severe sore arm and muscle aches were unknown at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Swelling
Clinical narrative: Swelling; This is a spontaneous report form a contactable consumer (Patient) reported that.  This is a spontaneous report from a contactable other hcp. A 48-years-old female patient received BNT162B2 (BioNTech/Pfizer vaccine solution for injection), dose 1 via an unspecified route of administration on 31Mar2021 (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient had treated with Restylane to lips and marionette lines and noticed that she had swelling on 02Apr2021, which she thought was normal. On 04Apr2021, she saw no difference. Her before and after looks the same. The event outcome was not recovered.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Drug hypersensitivity, Mass
Clinical narrative: This morning I woke up to some little bumps on the side of my face; some little bumps on the side of my face as like in an allergic reaction; This is a spontaneous report from a contactable consumer (patient). A 18-years-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EW0162), via an unspecified route on 10May2021 (at the age of 18-years) as dose 2, single in the right arm for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: Unknown), via an unspecified route on 12Apr2021 (at the age of 18-years) as dose 1, single for covid-19 immunisation. On 11May2021, the patient experienced and stated "I received her second vaccine yesterday and this morning I woke up with little dots to some little bumps on the side of my face as like in an allergic reaction. But it was only in the side of my face. It's not where my injection site is or anywhere else in my body, just my face". Patient did not received treatment for events. The outcome of the events was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Fatigue, Hyperhidrosis, Myalgia, Vomiting
Clinical narrative: Extreme diarrhea where everything eat and drink comes out as water / Almost immediately after consuming, must be near bathroom or will not make it. It has not let up nor changed forms; Extreme muscle aches; Some vomiting out of the blue; Sweating; Fatigue; This is a spontaneous report from a contactable healthcare professional, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via intramuscular route of administration in the right arm on an unknown date at 07:30 as a single dose for COVID-19 immunisation. The patient did not have any medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient previously received sulfur (MANUFACTURER UNKNOWN) and experienced drug allergy. On 19Mar2021 at 01:00, the patient experienced extreme diarrhea where everything she ate and drank came out as water. Almost immediately after consuming, she must be near bathroom or she will not make it. It had not let up nor changed forms and also had extreme muscle aches, some vomiting out of the blue, sweating and fatigue. The events did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme diarrhea where everything she ate and drank came out as water, almost immediately after consuming, she must be near bathroom or she will not make it, it had not let up nor changed forms and also had extreme muscle aches, some vomiting out of the blue, sweating and fatigue was not resolved at the time of this report. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the right arm on 08Apr2021 (at the age of 52-years-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Body temperature, Dizziness, Fatigue, Nausea
Clinical narrative: Body aches (severe); Stomach cramping in upper left and right quadrants, resulting in vomiting multiple times over 4+ hours; Stomach cramping in upper left and right quadrants, resulting in vomiting multiple times over 4+ hours; Extreme exhaustion; Dizziness; Shakiness; Nausea; Fever of 101; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 10May2021 at 16:45 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and know allergies to penicillin (PCN), cephalosporins, almonds and peaches. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified concomitant medication on an unknown date, for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 12Apr2021 at 16:45 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. The patient also previously received nitrofurantoin (MACROBID) on an unknown date for unknown indication and experienced drug allergy. On 11May2021 at 06:00, the patient experienced body aches (severe), extreme exhaustion, dizziness, shakiness, nausea and stomach cramping in the upper left and right quadrants, resulting in vomiting multiple times over 4 plus hours. On the same day, about 24 hours after injection the patient experienced a fever of 101 (unspecified units). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever of 101 (units unspecified), body aches (severe), extreme exhaustion, dizziness, shakiness, nausea and stomach cramping in upper left and right quadrants, resulting in vomiting multiple times over 4+ hours was resolving at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Tremor, Vomiting
Clinical narrative: Body aches (severe); Stomach cramping in upper left and right quadrants, resulting in vomiting multiple times over 4+ hours; Stomach cramping in upper left and right quadrants, resulting in vomiting multiple times over 4+ hours; Extreme exhaustion; Dizziness; Shakiness; Nausea; Fever of 101; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 10May2021 at 16:45 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma and know allergies to penicillin (PCN), cephalosporins, almonds and peaches. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified concomitant medication on an unknown date, for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 12Apr2021 at 16:45 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. The patient also previously received nitrofurantoin (MACROBID) on an unknown date for unknown indication and experienced drug allergy. On 11May2021 at 06:00, the patient experienced body aches (severe), extreme exhaustion, dizziness, shakiness, nausea and stomach cramping in the upper left and right quadrants, resulting in vomiting multiple times over 4 plus hours. On the same day, about 24 hours after injection the patient experienced a fever of 101 (unspecified units). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever of 101 (units unspecified), body aches (severe), extreme exhaustion, dizziness, shakiness, nausea and stomach cramping in upper left and right quadrants, resulting in vomiting multiple times over 4+ hours was resolving at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Body temperature, Diarrhoea, Pyrexia, Vomiting
Clinical narrative: Severe abdominal pain; Vomiting for 4 hours; Temp 101.2; Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 10May2021 at 15:45 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. Medical history included reflux and pennecillan allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within 2 weeks of vaccination. The patient previously received azithromycin (Z-PAC) and cefuroxime axetil (CEFTIN) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Apr2021 at 14:30 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. On 11May2021 at 05:30, the patient experienced severe abdominal pain, vomiting for 4 hours over and over, temp 101.2 and diarrhea. On 11May2021, the patient underwent body temperature test and the result was 101.2 (unspecified units). Therapeutic measures were taken as a result of severe abdominal pain, vomiting for 4 hours over and over, temp 101.2 and diarrhea and included treatment with unspecified anti-nausea drugs, acetaminophen and suppositories. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event vomiting for 4 hours over and over was resolved on 11May2021; while that of the events severe abdominal pain, temp 101.2 and diarrhea were resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: Back pain, Headache, Myalgia, Pain of skin, Pyrexia
Clinical narrative: Upper back pain beginning on day 5.; Fever for two days after the shot; Severe muscle aches; Skin pain; Headache; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 05May2021 at 08:45(at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history included psoriasis. The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive other vaccines within four weeks prior to the vaccination. Concomitant medications included triamcinolone acetonide (MANUFACTURER UNKNOWN) for unknown indication from unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration on 14Apr2021 at 08:45(at the age of 27-years-old) as a single dose for COVID-19 immunisation. On 05May2021 at 16:00 the patient experienced fever for two days after the shot, severe muscle aches, skin pain and headache. On 10May2021 the patient experienced upper back pain beginning on day 5. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event fever for two days after the shot was recovered with sequelae on 07May2021 while the events severe muscle aches, skin pain, headache and upper back pain was recovered with sequelae on an unknown date in May2021.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Disturbance in attention, Feeling abnormal, Memory impairment
Clinical narrative: Mild to fairly significant brain fog; Difficulty concentrating and remembering things; Difficulty concentrating and remembering things; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the left arm on 05May2021 at 13:15 (at the age of-52-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history (no significant conditions). The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN), lansoprazole (PREVACID), valaciclovir hydrochloride (VALTREX) and montelukast sodium (SINGULAIR) for unknown indication from an unknown date and unknown if ongoing. On 07May2021 at 14:30, the patient experienced mild to fairly significant brain fog, had difficulty concentrating and remembering things. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events brain fog, difficulty concentrating and remembering things were not recovered at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Rash
Clinical narrative: Pain right arm along with a rash on thighs; Pain right arm along with a rash on thighs; This is a spontaneous report from a contactable consumer, the patient. A 22-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176) via an unspecified route of administration in the right arm on 09May2021 at 12:30 (at the age of 22-years-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included sertraline hydrochloride (ZOLOFT) for unknown indications from unknown date and unknown if ongoing. On 11May2021, the patient experienced pain in right arm along with a rash on thighs. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events pain in right arm along with a rash on thighs were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.